To examine why prostate cancer is less susceptible to VEGF inhibition, we first compared gene expression between primary prostate tumors and a cancer type that typically does respond to VEGF inhibitors, renal cell carcinoma [25]. The gene discussed is VEGFA; the disease is renal cell carcinoma.